Eliaz Therapeutics Revenue and Competitors

Eliaz Therapeutics (ETI) was founded in 2015 by Isaac Eliaz, MD to leverage his significant expertise in Galectin-3 and Apheresis to develop and commercialize a therapeutic Apheresis device that removes Galectin-3 from the blood. Galectin-3 has a causal role in many life-threatening inflammatory and fibrotic diseases, immune dysregulation (including the cytokine storm), and cancer that do not have effective treatments today. The initial indication will be Acute Kidney Injury (AKI). AKI is a sudden decrease in kidney function with or without kidney damage, occurring over a few hours or days. Annual US hospitalizations for AKI are in excess of 4,000,000 and deaths exceed 500,000. Diabetes, hypertension, and advanced age are primary risk factors for acute kidney injury. It is increasingly recognized as an in-hospital complication of sepsis, heart conditions, surgery and Covid-19. Its most severe stage requires treatment with dialysis or renal transplant therapy. Acute kidney injury is also associated with higher likelihood of long-term care, incidence of chronic kidney disease and hospital mortality, and higher long-term health care costs. ETI anticipates receiving Breakthrough Device status and Investigational Device Exemption from the FDA in 2021.